cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

PR Newswire

CHARLOTTE, N.C., Dec. 19, 2025

Friday December 19, 2025, 4:20 p.m. Eastern Time

USA/Canada:	888-880-3330

Webcast/Webcast Replay link- available through December 19, 2026: https://app.webinar.net/13voDmbBlxj

cbdMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024


	September 30,	September 30,
	2025	2024
Assets


Cash and cash equivalents	$ 2,261,242	$ 2,452,553
Accounts receivable, net	1,040,887	983,910
Inventory, net	2,732,127	2,365,187
Inventory prepaid	214,795	159,006
Prepaid sponsorship	25,231	21,754
Prepaid expenses and other current assets	277,147	406,674
Total current assets	6,551,429	6,389,084

Other assets:
Property and equipment, net	277,377	454,268
Operating lease assets	703,934	85,817
Deposits for facilities	62,708	62,708
Intangible assets, net	2,124,502	2,889,580
Investment in other securities, noncurrent	700,000	700,000
Total other assets	3,868,521	4,192,373

Total assets	$ 10,419,950	$ 10,581,457
CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024
(continued)


	September 30,	September 30,
	2025	2024
Liabilities and shareholders' equity

Current liabilities:
Accounts payable	$ 1,173,642	$ 1,541,108
Accrued expenses	735,672	632,674
Accrued dividends	-	4,671,000
Deferred revenue	506,289	503,254
Operating leases - current portion	778,240	98,696
Convertible notes, at fair value	-	1,171,308
Total current liabilities	3,193,843	8,618,040

Long term liabilities:
Operating leases - long term portion	-	-
Total long term liabilities	-	-

Total liabilities	3,193,843	8,618,040

cbdMD, Inc. shareholders' equity:
Preferred stock, authorized 50,000,000W shares, $0.001
respectively	1,700	5,000
Common stock, authorized 150,000,000 shares, $0.001
respectively	8,917	492
Additional paid in capital	186,650,640	184,033,012
Comprehensive other expense	-	(7,189)
Accumulated deficit	(179,435,150)	(182,067,898)
Total cbdMD, Inc. shareholders' equity	7,226,107	1,963,417


Total liabilities and shareholders' equity	$ 10,419,950	$ 10,581,457

cbdMD, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED SEPTEMBER 30, 2025 and 2024


	September 30,	September 30,
	2025	2024

Gross Sales	$ 19,190,678	$ 19,922,319
Allowances	(210)	(440,152)
Total Net Sales	19,190,468	19,482,167
Cost of sales	7,222,213	7,486,626
Gross Profit	11,968,255	11,995,541

Operating expenses	14,130,845	15,310,951
Loss from operations	(2,162,590)	(3,315,410)
Decrease of contingent liability	-	74,580
Decrease (increase) in fair value of convertible debt	87,380	(429,789)
Interest expense (income)	34,308	(29,507)
Loss before provision for income taxes	(2,040,902)	(3,700,126)

Net (loss) income	(2,040,902)	(3,700,126)

Preferred dividends	2,334,501	4,004,001

Net Loss attributable to cbdMD, Inc. common shareholders	$ (4,375,403)	$ (7,704,127)

Net Loss per share:
Basic and diluted earnings per share	$ (1.09)	$ (14.29)
Weighted average number of shares Basic and Diluted:	4,022,629	539,069

cbdMD, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
FOR THE YEARS ENDED SEPTEMBER 30, 2025 and 2024




	September 30,	September 30,
	2025	2025

Net (Loss)	$ (2,040,902)	$ (3,700,126)
Comprehensive (Loss) income	(2,040,902)	(3,700,126)

Other Comprehensive income (loss)	$ 7,189	$ (7,189)
Preferred dividends	(2,334,501)	(4,004,001)
Comprehensive Loss attributable to cbdMD, inc. common shareholders	$ (4,368,214)	$ (7,711,316)

cbdMD, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEARS ENDED SEPTEMBER 30, 2025 and 2024


	September 30,	September 30,
	2025	2024

Cash flows from operating activities:
Net Loss	$ (2,040,902)	$ (3,700,126)
Adjustments to reconcile net loss to net
cash used by operating activities:
Stock based compensation	-	5,015
Restricted stock expense	14,121	11,885
Issuance of stock for services	86,657	-
Inventory and materials impairment	365,979	921,314
Intangibles amortization	765,078	697,510
Depreciation	361,063	452,326
Credit losses	382,588	54,322
Decrease in contingent liability	-	(74,580)
Increase in fair value of convertible debt	(87,380)	429,789
Gain on termination of operating lease asset	-	696,280
Amortization of operating lease asset	669,781	670,621
Changes in operating assets and liabilities:
Accounts receivable	(439,565)	177,858
Deposits	-	76,000
Inventory	(732,919)	766,472
Prepaid inventory	(55,789)	23,670
Prepaid expenses and other current assets	126,051	396,311
Accounts payable and accrued expenses	(261,883)	(1,124,141)
Operating lease liability	(608,354)	(1,151,326)
Deferred revenue / customer deposits	3,099	318,008
Cash flows from operating activities	(1,452,375)	(352,792)

Cash flows from investing activities:
Purchase of intangible assets	-	(100,000)
Purchase of property and equipment	(184,172)	(190,015)
Cash flows from investing activities	(184,172)	(290,015)

Cash flows from financing activities:
Proceeds from issuance of common stock	-	50,001
Note payable		1,247,499
Proceeds from issuance of preferred stock	1,445,236	-
Cash flows from financing activities	1,445,236	1,297,500
Net increase (decrease) in cash	(191,311)	654,693
Cash and cash equivalents, beginning of period	2,452,553	1,797,860
Cash and cash equivalents, end of period	$ 2,261,242	$ 2,452,553



Supplemental Disclosures of Cash Flow Information:
	2025	2024

Cash paid for interest	$ -	$ 74,638

Non-cash financing/investing activities:
Issuance of shares for conversion of debt and accrued interest	$ 1,079,639	$ 515,601
warehouse lease	$ (1,723,544)	$ -
Issuance of shares for intangible asset	$ -	$ 40,725
Conversion accrued preferred dividends to common stock	$ 7,008,151	$ -
Preferred dividends accrued but not paid	$ 2,334,501	$ 4,004,001

cbdMD, Inc.
SUPPLEMENTAL FINANCIAL INFORMATION
FOR THE YEARS ENDED SEPTEMBER 30, 2025 and 2024
(unaudited)


	Three Months Ended September 30,		Year Ended September 30,
	2025	2024	2025	2024

Revenue	$ 4,720,770	$ 4,556,367	$ 19,140,468	$19,482,167
Gross profit	2,777,135	$ 2,453,803	$ 11,968,255	$11,995,541
Gross margin	58.8 %	53.9 %	62.4 %	61.6 %
Operating Expenses	3,461,458	$ 2,770,356	$ 14,130,845	$15,310,951
Operating loss from operations	(684,323)	$ (316,553)	$ (2,162,590)	$ (3,315,410)
Corporate overhead operating expense (1)	399,501	$ 462,068	$ 1,816,563	$ 1,978,953
Non-GAAP adjusted (loss) income from operations	$ (284,822)	$ 145,515	$ (346,027)	$ (1,336,457)


GAAP loss from operations	$ (684,323)	$ (316,553)	$ (2,162,590)	$ (3,315,410)
Adjustments:
Depreciation & Amortization	262,065	287,783	1,126,141	1,149,836
Employee and director stock compensation (2)	7,754	5,881	13,595	43,688
Inventory adjustment (3)	113,008	588,160	113,008	588,160
Non-cash expense incurred as a credit (4)	-	-	-	439,926
contracts	-	-	-	72,101
Termination of HQ lease	-	(696,280)	-	(696,280)
Mergers and acquisitions expense	-	-	-	125,838
Non-GAAP adjusted loss from operations	$ (301,496)	$ (131,009)	$ (909,846)	$ (1,592,141)

Public Company Costs
Staff related expense	70,698	119,975	310,647	288,602
Accounting/legal expense	103,532	125,874	524,352	710,188
Professional outside services	41,496	73,843	291,455	310,448
Business insurance	176,021	136,495	676,514	626,027
Non-GAAP adjusted income from operations, excluding public	$ 90,251	$ 325,178	$ 893,122	$ 343,124


(1) Represents corporate overhead operating expenses
(2) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period
(3) Represents an operating expense related to inventory loss related to regulatory changes impacting labels and packaging and obsolete/expired inventory.
(4) Represents non-cash expense incurred as a credit provided to GNC to replace expired product.

today announced our financial results for the full fiscal year ended September 30, 2025.NYSE American: YCBD)cbdMD and Paw CBD,Herbal OasisCHARLOTTE, N.C.Dec. 19, 2025

For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science.

The Company reported a loss from operations of $2.1 million, representing a $1.2 million year-over-year improvement from a $3.3 million operating loss in fiscal 2024. As a result of balance-sheet actions completed during the year, including the conversion of Series A preferred equity, net book value improved from under $2.0 million to approximately $7.2 million at year-end. The Company took further steps this week to strengthen its balance sheet and raised an additional $2.25 million in gross proceeds from the sale of Series C Convertible Preferred Stock. Management believes the current capital structure provides flexibility to support growth initiatives and opportunities ahead in 2026.

"Fiscal 2025 marked an important inflection point for cbdMD as we delivered our third straight year of operating improvement while completing several foundational balance-sheet and compliance milestones," said Ronan Kennedy, CEO and CFO of cbdMD. "We believe our performance during the September quarter compared favorably with many of our public peers and reflects the early impact of strategic changes we made to our sales and marketing organization."

"Our core cbdMD business continues to gain traction, and our Herbal Oasis team is seeing consistent month-over-month improvement in case sell-through across key markets as distribution expands throughout the Southeast. Importantly, we have paired this commercial momentum with a disciplined approach to capital allocation and balance-sheet management."

"As federal policy discussions continue to evolve around cannabinoids and hemp-derived products, cbdMD remains focused on operating at the highest standards of safety, quality, and scientific rigor," Kennedy continued. "Since our founding, we have invested millions of dollars in GMP manufacturing, product testing, and compliance systems to ensure our products meet or exceed applicable regulatory expectations."

"We are very encouraged by the White House's executive order on Thursday. We believe decriminalization will allow significant investment to further prove the benefits of cannabinoids. Since our formation, we have invested millions to ensure we provide safe, effective cannabinoid products that meet high-GMP quality standards. What makes us most excited are the statements around Medicare supporting the reimbursement of full spectrum hemp for seniors. This gives us confidence the regulators will figure out how to rework the language in Novembers' H.R. 5371 to more palatable language. There are over 60 million seniors on Medicaid who have the potential to become regular consumers to our core market.

"We believe increasing regulatory clarity will encourage additional research and institutional investment across the category. With our long-standing emphasis on THC-free and broad-spectrum CBD formulations, as well as our experience responsibly operating in hemp-derived THC beverages, cbdMD is well positioned to adapt as regulatory frameworks mature."

"With a stronger balance sheet, restored exchange compliance, improving operations, and a disciplined approach to growth, we believe cbdMD enters calendar 2026 in a materially stronger position," Kennedy concluded. "Our focus remains on executing responsibly, investing in science and quality, and creating long-term value for shareholders."

Highlights for Fiscal 2025 and Notable Business Updates

Financial Highlights from our Fiscal Year 2025:

Pursuant to the disclosure requirements of the NYSE American Company Guide Section 610(b), cbdMD is reporting that its audited consolidated financial statements for the fiscal year ended September 30, 2025, included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 18, 2025, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to cbdMD's ability to continue as a going concern. This announcement does not represent any change or amendment to cbdMD's financial statements or to its Annual Report on Form 10-K for the fiscal year ended September 30, 2025.

We will host a conference call at 4:20 p.m., Eastern Time, on Friday, December 19, 2025, to discuss our September 30, 2025, fourth quarter and full fiscal year financial results and business progress.

CONFERENCE CALL DETAILS

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced THC-freewww.cbdmd.com www.pawcbd.com ATRxlabs.com Herbaloasis.com¹¹

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, continued cost reductions, potential need for additional working capital, evolving regulatory and legal requirements and potential changes in federal law and federal and state oversight of CBD, continued listing on the NYSE American, future profitability, development and sales of new products, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 as filed with the Securities and Exchange Commission (the "SEC") on December 19, 2025, and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

THC-free is defined as below the level of detection using validated scientific analytical methods.¹

Non-GAAP Financial Measures

This press release includes a financial measure that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). cbdMD, Inc. has included adjusted loss from operations because management uses this measure to assess operating performance in order to highlight trends in our business that may not otherwise be apparent when relying on financial measures calculated in accordance with GAAP. The adjusted operating loss has not been prepared in accordance with GAAP. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, net loss from operations as an indicator of our operating performance. Further, this non-GAAP financial measure, as presented by cbdMD, Inc., may not be comparable to similarly titled measures reported by other companies. cbdMD, Inc. has attached to this press release a reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure.

Contacts:

Investors:

IR@cbdmd.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-reports-third-consecutive-year-of-operating-improvement-strengthens-balance-sheet-and-regains-nyse-american-continued-listing-compliance-302647308.html

SOURCE cbdMD, Inc.

Herbal Oasis expanded into Texas through a distribution partnership with Morales Beverage Group. The brand now has established distribution in North Carolina, Florida, Alabama, Texas, Tennessee, and Minnesota, with the ability to ship directly to additional states where permitted.
At the end of September 2025, cbdMD completed $1.7 million in Series B Convertible Preferred equity financing, generating $1.5 million in net proceeds to support working capital and strengthen net book value.
The NYSE American formally notified the Company in a letter dated December 5, 2025, confirming that cbdMD has resolved all deficiencies related to Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
On December 18, 2025 cbdMD closed a $2.25 million Series C Convertible Preferred equity financing, generating $2.2 million in net proceeds from the sale of 1,000,000 shares of Series C Convertible Preferred Stock which have rights and preferences substantially the same as the Company's outstanding Series B Preferred Stock and are initially convertible at $2.25 per share, to further enhance equity and liquidity.
On December 15 2025, as amended December 18, 2025, the Company entered into a $20 million equity line of credit, providing cbdMD with a potential flexible and efficient mechanism to access capital under favorable market conditions. The ELOC is subject to an S-1 registration statement to be filed by the Company and SEC review.

Net sales totaled $19.1 million in fiscal 2025 compared to $19.5 million in fiscal 2024.
Our gross profit for the year was flat at 62% in fiscal 2025 compared to 62% in fiscal 2024.
Our loss from operations was $2.1 million in fiscal 2025 as compared to a loss of $3.3 million in fiscal 2024.
Our non-GAAP adjusted EBITDA loss from operations in fiscal 2025 was approximately $0.9 compared to our non-GAAP adjusted EBITDA from operations in fiscal 2024 of approximately $1.6. million.
Net loss attributable to common shareholders for fiscal 2025 was approximately $4.3 million or $0.51 per share as compared to a net loss for fiscal 2024 of approximately $7.7 million, or $14.29 per share. The improvement in fiscal 2025 was principally attributable to ongoing management's efforts on improving profitability.
At September 30, 2025, we had $2.3 million in cash on hand and working capital of approximately $3.4 million as compared to $2.4 million of cash and approximately negative $2.2 million of working capital (which includes $4.7 million of accrued Series A dividend payments) at September 30, 2024.
We reported direct to consumer (DTC) net sales of $14.7 million or 77% of total net sales in fiscal 2025, a decrease of $0.9 million, or 6% from fiscal 2024.